Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

@article{Lim2011FcGR,
  title={Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.},
  author={Sean H Lim and Andrew T. Vaughan and Margaret R Ashton-Key and Emily L. Williams and Sandra V. Dixon and H T Claude Chan and Stephen A Beers and Ruth R. French and Kerry Cox and A. J. Davies and K. N. Potter and C. Ian Mockridge and David Oscier and Peter W M Johnson and Mark S Cragg and Martin J. Glennie},
  journal={Blood},
  year={2011},
  volume={118 9},
  pages={2530-40}
}
The anti-CD20 mAb rituximab is central to the treatment of B-cell malignancies, but resistance remains a significant problem. We recently reported that resistance could be explained, in part, by internalization of rituximab (type I anti-CD20) from the surface of certain B-cell malignancies, thus limiting engagement of natural effectors and increasing mAb consumption. Internalization of rituximab was most evident in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), but the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 66 extracted citations

Resistance to Immunotherapeutic Antibodies in Cancer

Resistance to Targeted Anti-Cancer Therapeutics • 2013
View 8 Excerpts
Highly Influenced

A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates

International journal of molecular sciences • 2017
View 3 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Similar Papers

Loading similar papers…